Confirmed germline pathogenic / likely-pathogenic variant in DICER1 (RNase III endonuclea...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-DICER1-CONFIRMED-CARRIER |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN DIS-SOFT-TISSUE-SARCOMA DIS-WILMS |
| Sources | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 SRC-NCCN-OVARIAN-2025 SRC-SCHULTZ-DICER1-2018 SRC-STEWART-DICER1-REVIEW-2019 |
Red Flag Origin
| Definition | Confirmed germline pathogenic / likely-pathogenic variant in DICER1 (RNase III endonuclease essential for miRNA biogenesis). Autosomal- dominant; moderate-to-high penetrance for a characteristic tumor spectrum that combines rare childhood + adolescent + young-adult cancers. Cancer spectrum: pleuropulmonary blastoma (PPB, ~5-10% lifetime risk, most distinctive — childhood-onset pulmonary cystic / solid lesion progression Type I → II → III), Sertoli-Leydig cell tumor of the ovary (~6-15% lifetime in female carriers, adolescent / young adult), multinodular goiter (~75% lifetime, often presenting age 5-20), cystic nephroma (~5-10% childhood), embryonal rhabdomyo- sarcoma of cervix / urinary tract, pinealoblastoma + pituitary blastoma, nasal chondromesenchymal hamartoma. ~1 in 10,000 population frequency; recognition often follows family clustering of multiple tumor types. Patient has confir... |
|---|---|
| Clinical direction | investigate |
| Category | other |
Trigger Logic
{
"any_of": [
{
"finding": "germline_dicer1_pathogenic_variant_confirmed",
"value": true
},
{
"finding": "germline_dicer1_likely_pathogenic_variant",
"value": true
},
{
"finding": "dicer1_syndrome_clinical_criteria_met",
"value": true
}
],
"type": "lab_value"
}
Notes
Prevention-persona RedFlag for DICER1 confirmed-carrier cohort. Pediatric surveillance per International PPB Registry / IDSDB recommendations: - Chest CT q4-6 mo from birth to age 3, q6-12 mo to age 8. - Abdominal US q3-6 mo from birth to age 8. - Thyroid US baseline by age 8 + q3-5 y. - Pelvic US in female carriers from menarche. - Brain MRI baseline + symptom-driven. Surgery curative for PPB Type I when detected early; advanced PPB Type III (solid component) very aggressive. Risk-reducing oophorectomy not endorsed for Sertoli-Leydig prevention. STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode.
Used By
Indications
IND-DICER1-CARRIER-PREVENTION-OBSERVATION- IND-DICER1-CARRIER-PREVENTION-OBSERVATIONIND-DICER1-CARRIER-PREVENTION-SURVEILLANCE- IND-DICER1-CARRIER-PREVENTION-SURVEILLANCE
Sources
SRC-STEWART-DICER1-REVIEW-2019- Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1